trending Market Intelligence /marketintelligence/en/news-insights/trending/yuWzvMmXeYRPEp__-yta9w2 content esgSubNav
In This List

Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

Novo Nordisk A/S said the U.S. Food and Drug Administration approved a label expansion for the company's blockbuster diabetes drug Ozempic.

The U.S. regulator granted the label expansion to the injectable drug for reducing the risk of major adverse cardiovascular events — including cardiovascular death, nonfatal heart attack or nonfatal stroke — in adults with type 2 diabetes and established cardiovascular disease.

The approval was supported by results of a phase 3 trial called Sustain 6, in which Ozempic reduced the risk of major adverse heart events by 21% compared to placebo, according to a Jan. 16 news release.

The U.S. FDA first approved Ozempic in 2017 to improve glycemic control in adults with type 2 diabetes. Ozempic is also approved in the EU and Japan, among other territories.

SNL Image